Daily Brief : July 5: Battery recycling surge, FDA housekeeping, flat fees

HEADLINE

India's battery recycler BatX closes $11M Series A as critical minerals sourcing becomes a geopolitical priority.

THE BIG PICTURE

Today's stories pivot on a single anxiety: supply-chain self-sufficiency. A Gurugram startup raises growth capital to pull lithium, nickel, and cobalt out of used batteries rather than depend on imports; the FDA withdraws 34 stale drug approvals to tighten its regulatory catalog; and Bitcoin's network hashrate climbs to 928.9 exahashes per second while transaction fees collapse to 1 sat/vB, reflecting infrastructure becoming simultaneously more secure and more accessible. Sovereign resilience, regulatory discipline, and decentralized finance are all moving in the same direction.

WHAT HAPPENED

BatX Energies, a lithium-ion battery recycling company based in Gurugram, India, closed a Series A funding round of ₹105 crore, approximately $11 million. The round was led by IvyCap Ventures and included participation from Zephyr Peacock, Mankind Pharma Family Office, Excel Industries Family Office, and JITO. BatX uses a proprietary process to extract black mass from used lithium-ion cells, recovering lithium, nickel, cobalt, and manganese for reuse in battery manufacturing, along with secondary materials including plastic, aluminum, copper, and stainless steel. The company operates a battery shredding and hydrometallurgy facility with a current capacity of 5,000 metric tonnes and plans to use the capital to scale capacity, strengthen R&D, and develop Cathode Active Materials (CAM) production. IvyCap partner Vikram Gupta framed the investment as addressing a challenge of 'economic and strategic importance,' reflecting India's energy transition dependency on securing sustainable domestic access to critical minerals.

The U.S. Food and Drug Administration published two regulatory actions in the Federal Register on July 6, 2026. The first is the withdrawal of approval of 34 New Drug Applications (NDAs) held by Endo Operations Limited and related entities, effective August 5, 2026. The second is a correction notice to the FDA's Expedited Investigational New Drug (IND) Pilot Program, adjusting the docket for the June 24, 2026 request for comments on the agency's proposed fast-track IND pilot. Together, these actions signal ongoing FDA portfolio rationalization and acceleration of clinical trial pathways for early-stage drug development.

Bitcoin's network hashrate stands at 928.9 exahashes per second as of this morning, reflecting continued network security expansion. More notably, the mempool is effectively empty, with transaction fees flat across all priority tiers at 1 satoshi per vbyte. This level of congestion indicates minimal economic competition for block space, a condition typically observed during weekend periods and reflective of the network's growing baseline throughput capacity relative to transaction demand.

WATCHING

Watch for BatX's next capacity expansion announcement and whether India's government extends subsidy or tariff protection to domestic battery materials producers, a policy lever that many nations are now using to secure EV supply chains. On the regulatory front, the FDA's IND pilot program correction will signal the breadth of the final rule and how aggressively the agency is willing to compress early-stage clinical trial timelines; look for the comment period to close and a final guidance in the next 90 days.